REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc. (Nasdaq: RVPH) is a clinical-stage biopharmaceutical company that completed its business combination with blank-check company Tenzing Acquisition Corp in 2021. Tenzing Acquisition Corp conducted its initial public offering in 2020, targeting the life sciences and healthcare sector. Reviva focuses on developing novel central nervous system therapeutics, with lead candidate brilaroxazine in clinical trials for indications including schizophrenia and bipolar disorder. The company submitted an 8-K current report to the SEC on November 14, 2023, under accession number 0001437749-23-031981. For comprehensive filing history, clinical milestone tracking, and post-merger analytics on RVPH and the broader SPAC universe, sign up for SpacDesk.